Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques.
Waldmann TA, Lugli E, Roederer M, Perera LP, Smedley JV, Macallister RP, Goldman CK, Bryant BR, Decker JM, Fleisher TA, Lane HC, Sneller MC, Kurlander RJ, Kleiner DE, Pletcher JM, Figg WD, Yovandich JL, Creekmore SP. Waldmann TA, et al. Among authors: perera lp. Blood. 2011 May 5;117(18):4787-95. doi: 10.1182/blood-2010-10-311456. Epub 2011 Mar 8. Blood. 2011. PMID: 21385847 Free PMC article.
Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.
Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, Fleisher TA, Dubois SP, Perera LP, Stewart DM, Goldman CK, Bryant BR, Decker JM, Chen J, Worthy TA, Figg WD Sr, Peer CJ, Sneller MC, Lane HC, Yovandich JL, Creekmore SP, Roederer M, Waldmann TA. Conlon KC, et al. Among authors: perera lp. J Clin Oncol. 2015 Jan 1;33(1):74-82. doi: 10.1200/JCO.2014.57.3329. Epub 2014 Nov 17. J Clin Oncol. 2015. PMID: 25403209 Free PMC article. Clinical Trial.
IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion.
Conlon KC, Potter EL, Pittaluga S, Lee CR, Miljkovic MD, Fleisher TA, Dubois S, Bryant BR, Petrus M, Perera LP, Hsu J, Figg WD, Peer CJ, Shih JH, Yovandich JL, Creekmore SP, Roederer M, Waldmann TA. Conlon KC, et al. Among authors: perera lp. Clin Cancer Res. 2019 Aug 15;25(16):4945-4954. doi: 10.1158/1078-0432.CCR-18-3468. Epub 2019 May 29. Clin Cancer Res. 2019. PMID: 31142503 Free PMC article. Clinical Trial.
Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies.
Dubois SP, Miljkovic MD, Fleisher TA, Pittaluga S, Hsu-Albert J, Bryant BR, Petrus MN, Perera LP, Müller JR, Shih JH, Waldmann TA, Conlon KC. Dubois SP, et al. Among authors: perera lp. J Immunother Cancer. 2021 Apr;9(4):e002193. doi: 10.1136/jitc-2020-002193. J Immunother Cancer. 2021. PMID: 33883258 Free PMC article. Clinical Trial.
Smallpox vaccine with integrated IL-15 demonstrates enhanced in vivo viral clearance in immunodeficient mice and confers long term protection against a lethal monkeypox challenge in cynomolgus monkeys.
Zielinski RJ, Smedley JV, Perera PY, Silvera PM, Waldmann TA, Capala J, Perera LP. Zielinski RJ, et al. Among authors: perera lp, perera py. Vaccine. 2010 Oct 8;28(43):7081-91. doi: 10.1016/j.vaccine.2010.08.008. Epub 2010 Aug 20. Vaccine. 2010. PMID: 20728526 Free PMC article.
84 results